Glow Stack (BPC-157 + TB-500 + GHK-Cu)
A research overview of the combination of BPC-157, TB-500, and GHK-Cu, building on the Wolverine recovery stack with the addition of GHK-Cu for tissue remodeling and gene expression modulation. BPC-157 drives angiogenesis and structural repair. TB-500 drives cell migration and anti-inflammatory signaling. GHK-Cu modulates over 4,000 genes and promotes collagen and elastin synthesis.
Science simplified
The Glow Stack builds on the Wolverine Stack by adding GHK-Cu, a naturally occurring copper peptide that declines significantly with age and is studied for skin repair, collagen synthesis, and tissue remodeling. The combination targets injury recovery and tissue repair while simultaneously supporting skin health and cellular regeneration. All three compounds have independent research support but no human trials exist for this specific combination.
Best researched for
Recovery · skin repair · tissue remodeling
Evidence stage
Individual compound data · no combination trials
Approval status
No compounds FDA-approved · research use only
Human Trials / Animal Studies / Mixed
Compound Evidence Levels
None
Combination Trial Data
3
Compounds
Tissue + Skin
Primary Research Focus
PSI Verdict
Supported by evidence
Skin and collagen peptide stacks combine compounds with distinct mechanisms for skin repair, collagen synthesis, and anti-inflammatory activity. GHK-Cu has documented human evidence for topical wound healing and collagen synthesis. Collagen peptides have randomized controlled trial data for skin elasticity. The individual evidence bases for skin-focused compounds are among the stronger in this library.
Not yet established
Combination evidence for skin peptide stacks does not exist. Systemic delivery of GHK-Cu and the interaction between injectable and oral compounds in a combined skin protocol have not been studied. The assumption that combining individually active compounds produces superior outcomes is unvalidated.
Confidence level
The Glow Stack benefits from having two of the better-evidenced individual compounds for skin applications in this library. The combination itself is unstudied. For skin applications specifically, the individual compound evidence is strong enough to be worth noting, the combination evidence gap is consistent with every other stack in this library.
Stack Rationale
Extension of the Wolverine Stack: This stack extends the Wolverine Stack (BPC-157 + TB-500) by adding GHK-Cu as a third compound targeting tissue remodeling and gene expression modulation.
BPC-157: Promotes angiogenesis and structural repair via VEGF and GH receptor pathways. Strong preclinical data across tendon, ligament, muscle, bone, and gut tissue types.
TB-500: Drives actin-mediated cell migration and suppresses TNF-α and IL-6. A synthetic fragment of thymosin beta-4 studied for regenerative and anti-inflammatory activity.
GHK-Cu: Adds a third layer, broad gene expression modulation, collagen and elastin synthesis promotion, and tissue remodeling via TGF-β and VEGF upregulation. GHK-Cu plasma levels decline ~60% between age 20 and 60, making it relevant to both acute repair and age-related tissue maintenance research.
Important limitation: No combination trials exist for this three-compound protocol. The stack rationale is derived entirely from the individual compound profiles. Interaction effects, safety of combined use, and additive or synergistic outcomes are unknown.
In everyday terms: The Glow Stack adds GHK-Cu to the Wolverine recovery protocol. GHK-Cu is a copper peptide your body naturally produces that declines by about 60% between your 20s and 60s. It acts like a master reset signal for aging cells, turning on repair genes and turning off inflammation genes. Adding it to BPC-157 and TB-500 extends the protocol from injury recovery into skin and tissue remodeling.
Compound Profiles
A gastric pentadecapeptide that promotes angiogenesis and growth factor signaling across multiple tissue types. Strong and consistent animal data for tendon, ligament, muscle, bone, and gut repair. Limited human clinical data. Classified as Human Trials (Moderate Evidence).
A synthetic fragment of thymosin beta-4 that promotes actin-mediated cell migration and anti-inflammatory signaling. Early-phase human trial data exists for wound healing via the parent molecule. Classified as Animal Studies (Preliminary Evidence).
A naturally occurring tripeptide-copper complex that modulates over 4,000 human genes, promotes collagen and elastin synthesis, and resets gene expression patterns toward healthier phenotypes. Extensive safety data from cosmetic and dermatological use. Animal Studies through Human Trials contextual, strong topical evidence, more limited systemic data.
Mechanistic Comparison
| Dimension | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Primary mechanism | Angiogenesis + GH receptor signaling | Actin upregulation + cell migration | Gene expression modulation + collagen synthesis |
| Anti-inflammatory | Moderate via growth factors | Strong. TNF-α, IL-6 suppression | Metalloproteinase modulation |
| Tissue targets | Tendon, ligament, gut, bone | Musculoskeletal, cardiac, dermal | Skin, connective tissue, wound repair |
| Evidence level | Human Trials | Animal Studies | Animal Studies to Human Trials (contextual) |
Evidence Summary
What people commonly research this for
- , Injury recovery combined with skin and tissue remodeling
- , Collagen synthesis and skin repair research
- , Comprehensive regenerative protocol research
Individual compound evidence is moderate to preliminary. No combination trials exist. Not FDA-approved.
Individual Compound Evidence
BPC-157 is rated Human Trials (Moderate Evidence) with strong and consistent animal data across multiple tissue types and limited human clinical data. TB-500 is rated Animal Studies (Preliminary Evidence) with early-phase human trial data for wound healing via thymosin beta-4. GHK-Cu is rated Animal Studies through Human Trials contextual with extensive cosmetic use data and gene expression modulation research demonstrating effects on over 4,000 human genes.
Combination Evidence
No controlled studies have evaluated this three-compound protocol. The stack rationale is mechanistic, combining structural repair (BPC-157), cellular migration and anti-inflammatory signaling (TB-500), and gene expression modulation with collagen synthesis (GHK-Cu). Whether these compounds interact or produce additive effects is not established in published research.
Safety Considerations
Individual Safety Profiles
BPC-157 has a favorable safety profile in animal studies with limited human safety data. TB-500, via the parent molecule thymosin beta-4, has early-phase human trial data showing a generally favorable safety profile. GHK-Cu has an excellent safety profile from decades of cosmetic and dermatological use, considered non-toxic at therapeutic concentrations.
Combination Safety. Unknown
No safety data exists for this three-compound protocol. Drug interaction potential, combined tissue effects, and cumulative dosing considerations have not been studied. The absence of combination data means safety cannot be assumed. Caution is warranted for any untested multi-compound protocol.
Research Context
Researchers interested in the individual mechanisms behind this stack can review the full compound profiles for BPC-157, TB-500, and GHK-Cu.
The two-compound foundation of this stack is covered on the Wolverine Stack (BPC-157 + TB-500) page.
For a related gut-focused recovery protocol, see the Klow Stack.
For a broader overview of peptides studied for musculoskeletal growth and repair, see the peptides for muscle growth roundup.
For peptides studied for skin health and remodeling, see the peptides for skin roundup.
This stack is reviewed in the context of the broader injury recovery research literature on this site.
Medical Disclaimer
This page is for informational and educational purposes only and does not constitute medical advice. GHK-Cu and BPC-157 are research compounds not approved for human therapeutic use as a stack. Always consult a qualified healthcare professional. PSI aggregates publicly available research and does not conduct original clinical trials.